Rabbit SARS-CoV-2 (2019-nCoV) Spike Polyclonal Antibody | anti-SARS-CoV-2 antibody

SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit PAb, Antigen Affinity Purified

Cat. Num. AAA8119545

• Reactivity: SARS-CoV-2
• Applications: Western Blot, ELISA
• Purity: Protein A & Antigen Affinity
• Synonyms: SARS-CoV-2 (2019-nCoV) Spike; Polyclonal Antibody; SARS-CoV-2 (2019-nCoV) Spike Antibody; Rabbit PAb; Antigen Affinity Purified; anti-SARS-CoV-2 antibody

• Host: Rabbit
• Reactivity: SARS-CoV-2
• Clonality: Polyclonal
• Isotype: Rabbit IgG
• Specificity: SARS-CoV-2 (2019-nCoV) Spike S-His Protein
• Purity/Purification: Protein A & Antigen Affinity
• Form/Format: Liquid. 0.2um filtered solution in PBS

• Applicable Applications for anti-SARS-CoV-2 antibody: Western Blot (WB), ELISA (EIA)
• Application Notes: WB: 1:1000-1:5000; ELISA: 1:5000-1:10,000; Antibody's applications haven't been validated with corresponding virus positive samples.
• Immunogen: Recombinant SARS-CoV-2 (2019-nCoV) Spike S-His Protein
• Conjugation: Unconjugated
• Cross-reactivity: Has cross-reactivity in ELISA and WB with; SARS-CoV-2 (2019-nCoV) Spike RBD-mFc Protein ; SARS-CoV Spike S1-His Protein ; SARS-CoV Spike RBD-His Protein
• Preparation: Produced in rabbits immunized with purified, recombinant SARS-CoV-2 (2019-nCoV) Spike S1-His Recombiant Protein (HPLC-verified). The specific IgG was purified by SARS-CoV-2/2019-nCoV Spike affinity chromatography.
• Preparation and Storage: This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Preservative-Free. Avoid repeated freeze-thaw cycles.; This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Western Blot (WB)

(Anti-SARS-S1 rabbit polyclonal antibody at 1:2000 dilution. Lane A: SARS-CoV Spike S1 (5ng) Lane B: SARS-CoV Spike RBD (5ng) Lane C: SARS-CoV-2 (2019-nCoV) Spike S1 (5ng) Lane D: SARS-CoV-2 (2019-nCoV) Spike RBD (5ng) Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions.)

Related Product Information for anti-SARS-CoV-2 antibody

Background: The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.

References

Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.